Gilead Presents Long-Term Data on Seladelpar for Rare Liver Disease Treatment

Friday, 15 November 2024, 10:14

Gilead unveils pivotal data on Seladelpar from the Phase 3 ASSURE study, demonstrating efficacy in treating rare liver disease. The results reveal that 81% of patients with PBC achieved a composite response while maintaining safety. This research marks a crucial advancement in hepatology and therapeutic options.

Benzinga — Gilead Presents Long-Term Data on Seladelpar for Rare Liver Disease Treatment

Significant Findings on Seladelpar

Gilead has released long-term data from its Phase 3 ASSURE study focusing on Seladelpar as a treatment for *Primary Biliary Cholangitis (PBC)*. The study shows

81% of patients treated with Livdelzi achieving a composite response
Progressive safety profile over extended follow-ups

Implications for Patient Care

This data not only positions Seladelpar as a key player in treating rare liver diseases but also enhances understanding of patient care strategies in hepatology.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Significant Findings on Seladelpar

Implications for Patient Care

Related posts